Global Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report 2015-2018 & 2027 By Brand (Opdivo, Revlimid, Zejula) & Indication (Lung Cancer, Lymphoma, Multiple Myeloma) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 16, 2018--The “Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 - 2027” report has been added to ResearchAndMarkets.com’s offering.
The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, progressing at a CAGR of 7.3% during the forecast period.
Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.
Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immuno-therapeutic is expected to trail behind the latter by 2027.
Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.
Further key findings from the report suggest:North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027 In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027 Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement Some of the key companies present in the market are Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.
Key Topics Covered:
Chapter 1 Methodology And Scope 1.1 Research Methodology 1.2 Research Scope And Assumptions 1.3 List Of Abbreviations
Chapter 2 Executive Summary 2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope 3.1 Market Segmentation
Chapter 4 Market Definitions
Chapter 5 Industry Outlook 5.1 Business Segment Trend Analysis 5.2 Pricing Analysis 5.3 Market Variable Analysis 5.3.1 Market Drivers Analysis 126.96.36.199 Accelerated Approvals Expedite Market Launch 188.8.131.52 Immuno-Oncology Therapies As First Line Treatment 5.3.2 Market Restraints Analysis 184.108.40.206 High Therapy Costs Hinders Market Access 5.4 Business Environment Analysis Tools 5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological) 5.4.2 Porter’s Five Forces Analysis
Chapter 6 Competitive & Vendor Landscape 6.1 Market Participation Categorization 6.1.1 Market Leaders 6.1.2 Innovators 6.2 Strategic Initiatives & Outcome Analysis 6.2.1 List Of Key Strategies, By Company 6.4 List Of Key Companies, By Region 6.5 List Of Key Companies, By Indication 6.6 List Of Key Companies, By Brands 6.7 Company Market Share Analysis
Chapter 7 Regulatory And Political Forces 7.1 Regulatory Landscape 7.1.1 North America 7.1.2 Europe 7.1.3 Asia Pacific 7.1.4 Middle East & Africa 7.1.5 Latin America
Chapter 8 Brands Business Analysis 8.1 Blockbuster Oncology Brands Market: Brand Analysis 8.1.1. Tagrisso 8.1.2 Tecentriq 8.1.3 Ibrance 8.1.4 Perjeta 8.1.5 Zejula 8.1.6 Gazyva 8.1.7 Revlimid 8.1.8 Darzalex 8.1.9 Imbruvica 8.1.10 Opdivo 8.1.11 Keytruda
Chapter 9 Indications Business Analysis 9.1. Blockbuster Oncology Brands: Indications Movement Analysis 9.1.1. Lung Cancer 9.1.2 Breast Cancer 9.1.3 Multiple Myeloma 9.1.4 Lymphoma 9.1.5 Others
Chapter 10 Regional Business Analysis 2015-2027
Chapter 11 Company ProfilesBristol Myers Squibb Merck & Co. Roche Pfizer Astrazeneca Tesaro
For more information about this report visit https://www.researchandmarkets.com/research/xq5svd/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181116005306/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/16/2018 10:11 AM/DISC: 11/16/2018 10:10 AM